{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:57:11Z","timestamp":1780487831705,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00228-025-03905-8","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:18:36Z","timestamp":1757161116000},"page":"1795-1805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A real-world pharmacovigilance study of FDA Adverse Event Reporting System events for gefitinib and docetaxel"],"prefix":"10.1007","volume":"81","author":[{"given":"Chengqian","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingge","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"3905_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216022","volume":"554","author":"Y Tian","year":"2023","unstructured":"Tian Y, Xu L, Li X, Li H, Zhao M (2023) SMARCA4: current status and future perspectives in non-small-cell lung cancer. Cancer Lett 554:216022. https:\/\/doi.org\/10.1016\/j.canlet.2022.216022","journal-title":"Cancer Lett"},{"issue":"6","key":"3905_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/coc.0000000000001088","volume":"47","author":"J Xu","year":"2024","unstructured":"Xu J, Tian L, Qi W, Lv Q, Wang T (2024) Advancements in NSCLC: from pathophysiological insights to targeted treatments. Am J Clin Oncol 47(6):291\u2013303. https:\/\/doi.org\/10.1097\/coc.0000000000001088","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"3905_CR3","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/s1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S et al (2017) Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 18(11):1454\u20131466. https:\/\/doi.org\/10.1016\/s1470-2045(17)30608-3","journal-title":"Lancet Oncol"},{"issue":"16","key":"3905_CR4","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/jco.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T et al (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non\u2013small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24(16):2549\u20132556. https:\/\/doi.org\/10.1200\/jco.2005.04.9866","journal-title":"J Clin Oncol"},{"issue":"13","key":"3905_CR5","first-page":"1381","volume":"50","author":"T Konishi","year":"2023","unstructured":"Konishi T, Komatsu S, Takeda R, Kanazawa H, Soga K, Shimomura K et al (2023) Safety and efficacy of neoadjuvant chemotherapy (UDON: 5-FU, Docetaxel, and Nedaplatin) for esophageal cancer. Gan To Kagaku Ryoho 50(13):1381\u20131383","journal-title":"Gan To Kagaku Ryoho"},{"issue":"12","key":"3905_CR6","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1111\/1759-7714.14465","volume":"13","author":"K Asami","year":"2022","unstructured":"Asami K, Ando M, Nishimura T, Yokoi T, Tamura A, Minato K et al (2022) A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01). Thorac Cancer 13(12):1827\u20131836. https:\/\/doi.org\/10.1111\/1759-7714.14465","journal-title":"Thorac Cancer"},{"issue":"4","key":"3905_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100191","volume":"6","author":"K Hotta","year":"2021","unstructured":"Hotta K, Saeki S, Yamaguchi M, Harada D, Bessho A, Tanaka K et al (2021) Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902\/OLCSG0905 phase II study. ESMO Open 6(4):100191. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100191","journal-title":"ESMO Open"},{"key":"3905_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1424980","author":"Q Jie","year":"2024","unstructured":"Jie Q, Li Y, Jing L, Chen J, Li Y (2024) Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1424980","journal-title":"Front Pharmacol"},{"issue":"7","key":"3905_CR9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"issue":"6","key":"3905_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188967","volume":"1878","author":"S Singh","year":"2023","unstructured":"Singh S, Sadhukhan S, Sonawane A (2023) 20 years since the approval of first EGFR-TKI, gefitinib: insight and foresight. Biochimica et Biophysica Acta (BBA) 1878(6):188967. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188967","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"3","key":"3905_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/17425247.2019.1583644","volume":"16","author":"E Zhang","year":"2019","unstructured":"Zhang E, Xing R, Liu S, Li P (2019) Current advances in development of new docetaxel formulations. Expert Opin Drug Deliv 16(3):301\u2013312. https:\/\/doi.org\/10.1080\/17425247.2019.1583644","journal-title":"Expert Opin Drug Deliv"},{"issue":"9","key":"3905_CR12","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.3390\/curroncol31090423","volume":"31","author":"AM Perez","year":"2024","unstructured":"Perez AM, Haberland NI, Miteva M, Wikramanayake TC (2024) Chemotherapy-induced alopecia by docetaxel: prevalence, treatment and prevention. Curr Oncol 31(9):5709\u20135721. https:\/\/doi.org\/10.3390\/curroncol31090423","journal-title":"Curr Oncol"},{"issue":"7","key":"3905_CR13","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/s1470-2045(23)00230-9","volume":"24","author":"CL Vale","year":"2023","unstructured":"Vale CL, Fisher DJ, Godolphin PJ, Rydzewska LH, Boher JM, Burdett S et al (2023) Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol 24(7):783\u2013797. https:\/\/doi.org\/10.1016\/s1470-2045(23)00230-9","journal-title":"Lancet Oncol"},{"issue":"10","key":"3905_CR14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2174\/1567201817666200623121633","volume":"17","author":"C Misra","year":"2020","unstructured":"Misra C, Raza K, Goyal AK (2020) The scope and challenges of vesicular carrier-mediated delivery of docetaxel for the management of cancer. Curr Drug Deliv 17(10):874\u2013884. https:\/\/doi.org\/10.2174\/1567201817666200623121633","journal-title":"Curr Drug Deliv"},{"issue":"20 Pt 1","key":"3905_CR15","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1158\/1078-0432.Ccr-06-0200","volume":"12","author":"A Hurria","year":"2006","unstructured":"Hurria A, Fleming MT, Baker SD, Kelly WK, Cutchall K, Panageas K et al (2006) Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 12(20 Pt 1):6100\u20136105. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-0200","journal-title":"Clin Cancer Res"},{"key":"3905_CR16","doi-asserted-by":"publisher","unstructured":"Hu Q (2020) Application of related adverse reactions and nursing measures of gefitinib in patients with advanced lung cancer. J Chin Prescr Drug 18(11):19\u201320. https:\/\/doi.org\/10.3969\/j.issn.1671-945X.2020.11.010","DOI":"10.3969\/j.issn.1671-945X.2020.11.010"},{"issue":"1","key":"3905_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.amjopharm.2011.02.004","volume":"9","author":"WF Gellad","year":"2011","unstructured":"Gellad WF, Grenard JL, Marcum ZA (2011) A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother 9(1):11\u201323. https:\/\/doi.org\/10.1016\/j.amjopharm.2011.02.004","journal-title":"Am J Geriatr Pharmacother"},{"issue":"9","key":"3905_CR18","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","volume":"24","author":"S Dearden","year":"2013","unstructured":"Dearden S, Stevens J, Wu YL, Blowers D (2013) Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 24(9):2371\u20132376. https:\/\/doi.org\/10.1093\/annonc\/mdt205","journal-title":"Ann Oncol"},{"issue":"1","key":"3905_CR19","doi-asserted-by":"publisher","first-page":"100107","DOI":"10.1016\/j.jtocrr.2020.100107","volume":"2","author":"K Ninomiya","year":"2020","unstructured":"Ninomiya K, Teraoka S, Zenke Y et al (2020) Japanese lung cancer society guidelines for stage IV NSCLC with EGFR mutations. JTO Clin Res Rep. 2(1):100107. https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100107","journal-title":"JTO Clin Res Rep."},{"issue":"1","key":"3905_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23834-1","volume":"12","author":"Y Yin","year":"2022","unstructured":"Yin Y, Shu Y, Zhu J, Li F, Li J (2022) A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib. Sci Rep 12(1):19555. https:\/\/doi.org\/10.1038\/s41598-022-23834-1","journal-title":"Sci Rep"},{"issue":"11","key":"3905_CR21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.2165\/00019053-200119110-00005","volume":"19","author":"GL Plosker","year":"2001","unstructured":"Plosker GL, Hurst M (2001) Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer. Pharmacoeconomics 19(11):1111\u20131134. https:\/\/doi.org\/10.2165\/00019053-200119110-00005","journal-title":"Pharmacoeconomics"},{"issue":"22","key":"3905_CR22","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMp1809643","volume":"379","author":"R Platt","year":"2018","unstructured":"Platt R, Brown JS, Robb M, McClellan M, Ball R, Nguyen MD, Sherman RE (2018) The FDA sentinel initiative-an evolving national resource. N Engl J Med 379(22):2091\u20132093. https:\/\/doi.org\/10.1056\/NEJMp1809643","journal-title":"N Engl J Med"},{"issue":"14","key":"3905_CR23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/fon-2023-0814","volume":"20","author":"PJ Goebell","year":"2024","unstructured":"Goebell PJ, Raina R, Chen S, Rege S, Shah R, Grossman JP, Waldeck AR (2024) Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncol 20(14):903\u2013918. https:\/\/doi.org\/10.2217\/fon-2023-0814","journal-title":"Future Oncol"},{"issue":"12","key":"3905_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114074","volume":"9","author":"B Chen","year":"2014","unstructured":"Chen B, Zheng J, Zeng Y, Li B, Xie B, Zheng J et al (2014) Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism. PLoS One 9(12):e114074. https:\/\/doi.org\/10.1371\/journal.pone.0114074","journal-title":"PLoS One"},{"issue":"7","key":"3905_CR25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/14740338.2016.1192605","volume":"15","author":"EH Hsiue","year":"2016","unstructured":"Hsiue EH, Lee JH, Lin CC, Yang JC (2016) Safety of gefitinib in non-small cell lung cancer treatment. Expert Opin Drug Saf 15(7):993\u20131000. https:\/\/doi.org\/10.1080\/14740338.2016.1192605","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"3905_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020792","volume":"22","author":"T Ohmori","year":"2021","unstructured":"Ohmori T, Yamaoka T, Ando K, Kusumoto S, Kishino Y, Manabe R, Sagara H (2021) Molecular and clinical features of EGFR-TKI-associated lung injury. Int J Mol Sci 22(2):792. https:\/\/doi.org\/10.3390\/ijms22020792","journal-title":"Int J Mol Sci"},{"key":"3905_CR27","first-page":"38","volume":"15","author":"W Wang","year":"2022","unstructured":"Wang W, Zhao X, Mi Y (2022) 49 cases of adverse drug reactions caused by gefitinib in China recently. Chin J of Clinical Rational Drug Use 15:38","journal-title":"Chin J of Clinical Rational Drug Use"},{"key":"3905_CR28","first-page":"3017","volume":"29","author":"L Ma","year":"2018","unstructured":"Ma L, Shi JF, Tong N (2018) Study on adverse reactions of paclitaxel drugs. Chin Pharm 29:3017","journal-title":"Chin Pharm"},{"issue":"4","key":"3905_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4103\/0378-6323.178903","volume":"82","author":"AB Mehta","year":"2016","unstructured":"Mehta AB, Nadkarni NJ, Patil SP, Godse KV, Gautam M, Agarwal S (2016) Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 82(4):371\u20138. https:\/\/doi.org\/10.4103\/0378-6323.178903","journal-title":"Indian J Dermatol Venereol Leprol."},{"issue":"4","key":"3905_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","volume":"66","author":"G Curigliano","year":"2016","unstructured":"Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D et al (2016) Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin 66(4):309\u2013325. https:\/\/doi.org\/10.3322\/caac.21341","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"3905_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","volume":"1","author":"K Anand","year":"2019","unstructured":"Anand K, Ensor J, Trachtenberg B, Bernicker EH (2019) Osimertinib-induced cardiotoxicity: a retrospective review of the FDA Adverse Events Reporting System (FAERS). JACC CardioOncol. 1(2):172\u20138. https:\/\/doi.org\/10.1016\/j.jaccao.2019.10.006","journal-title":"JACC CardioOncol."},{"issue":"4","key":"3905_CR32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","volume":"21","author":"DS Ettinger","year":"2023","unstructured":"Ettinger DS, Wood DE, Aisner DL et al (2023) NCCN guidelines\u00ae insights: non-small cell lung cancer, version 2.2023. J Natl Compr Canc Netw 21(4):340\u2013350. https:\/\/doi.org\/10.6004\/jnccn.2023.0020","journal-title":"J Natl Compr Canc Netw"},{"key":"3905_CR33","doi-asserted-by":"publisher","unstructured":"Chinese Society of Lung Cancer, Chinese Anti-Cancer Association (2019) [EGFR-TKI ADR Management Chinese Expert Consensus]. Zhongguo Fei Ai Za Zhi 22(2):57\u201381. https:\/\/doi.org\/10.3779\/j.issn.1009-3419.2019.02.01","DOI":"10.3779\/j.issn.1009-3419.2019.02.01"},{"issue":"4","key":"3905_CR34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s10741-021-10151-4","volume":"27","author":"I Fabiani","year":"2022","unstructured":"Fabiani I, Panichella G, Aimo A, Grigoratos C, Vergaro G, Pugliese NR, Taddei S, Cardinale DM, Passino C, Emdin M, Giannoni A (2022) Subclinical cardiac damage in cancer patients before chemotherapy. Heart Fail Rev 27(4):1091\u20131104. https:\/\/doi.org\/10.1007\/s10741-021-10151-4","journal-title":"Heart Fail Rev"},{"issue":"3","key":"3905_CR35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/1078155219868761","volume":"26","author":"Y Noguchi","year":"2020","unstructured":"Noguchi Y, Kawashima Y, Maruyama M, Kawara H, Tokuyama Y, Uchiyama K et al (2020) Current status of eye disorders caused by docetaxel administration every 3 weeks: a case-control study in Japanese patients. J Oncol Pharm Pract 26(3):655\u2013665. https:\/\/doi.org\/10.1177\/1078155219868761","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"3905_CR36","first-page":"737","volume":"43","author":"Y Noguchi","year":"2016","unstructured":"Noguchi Y, Kawashima Y, Kawara H, Tokuyama Y, Tamura Y, Uchiyama K et al (2016) A retrospective analysis of epiphora due to docetaxel. Gan To Kagaku Ryoho 43(6):737\u2013741","journal-title":"Gan To Kagaku Ryoho"},{"issue":"1","key":"3905_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/nyas.13121","volume":"1374","author":"DG Goswami","year":"2016","unstructured":"Goswami DG, Tewari-Singh N, Agarwal R (2016) Corneal toxicity induced by vesicating agents and effective treatment options. Ann N Y Acad Sci 1374(1):193\u2013201. https:\/\/doi.org\/10.1111\/nyas.13121","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"3905_CR38","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.ophtha.2018.05.005","volume":"125","author":"EJ Wladis","year":"2018","unstructured":"Wladis EJ, Aakalu VK, Yen MT, Bilyk JR, Sobel RK, Mawn LA (2018) Balloon dacryoplasty for congenital nasolacrimal duct obstruction: a report by the American Academy of Ophthalmology. Ophthalmology. 125(10):1654\u20131657. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.005","journal-title":"Ophthalmology."},{"issue":"19","key":"3905_CR39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.12968\/bjon.2022.31.19.989","volume":"31","author":"A Mitchell","year":"2022","unstructured":"Mitchell A, Strafford M, Tavares S (2022) The renal system and associated disorders. Br J Nurs 31(19):989\u2013996. https:\/\/doi.org\/10.12968\/bjon.2022.31.19.989","journal-title":"Br J Nurs"},{"issue":"5","key":"3905_CR40","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/01.mnh.0000170753.41279.70","volume":"14","author":"P Gil","year":"2005","unstructured":"Gil P, Justo S, Castilla MA, Criado C, Caramelo C (2005) Cardio-renal insufficiency: the search for management strategies. Curr Opin Nephrol Hypertens 14(5):442\u2013447. https:\/\/doi.org\/10.1097\/01.mnh.0000170753.41279.70","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03905-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03905-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03905-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:43:46Z","timestamp":1764909826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03905-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3905"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03905-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}